Citigroup Inc Sage Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$7.02 - $13.08 $47,736 - $88,944	-6,800 Reduced 14.56%	39,900 $287,000
Q2 2024 Aug 12, 2024	BUY	$10.58 - $17.9 $494,086 - $835,929	46,700 New	46,700 $507,000
Q1 2023 May 11, 2023	SELL	$37.27 - $46.57 $1.81 Million - $2.26 Million	-48,600 Reduced 70.85%	20,000 $839,000
Q4 2022 Feb 09, 2023	BUY	$32.2 - $43.61 $1.56 Million - $2.12 Million	48,600 Added 243.0%	68,600 $2.62 Million
Q2 2022 Aug 10, 2022	SELL	$27.52 - $37.99 $35,776 - $49,387	-1,300 Reduced 6.1%	20,000 $646,000
Q4 2021 Feb 10, 2022	BUY	$37.06 - $47.11 $789,378 - $1 Million	21,300 New	21,300 $906,000

218

46.4M

847K

188K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.